To address whether LCN2-targeting agents can improve the therapeutic efficacy of sorafenib, we established four HCC patient-derived xenograft (PDX) models in NSG (non-obese diabetic; severe combined immunodeficiency; interleukin-2 receptor gamma chain null) mice. This evidence concerns the gene LCN2 and hepatocellular carcinoma.